| 2026-02-23 |
详情>>
业绩披露：
2025年年报每股收益-4.97美元,归母净利润-6.85亿美元,同比去年增长-112.42%
|
| 2026-02-17 |
详情>>
股本变动：
变动后总股本1551.50万股
|
| 2026-01-30 |
股东大会：
将于2026-02-23召开股东大会
会议内容 ▼▲
- 1.To consider and vote on a proposal to adopt (i) the Agreement and Plan of Merger, dated as of October 25, 2025 (the “Merger Agreement”), among Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland (“Novartis”), Ajax Acquisition Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Merger Sub”), and the Company, pursuant to which, on the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving the Merger as an indirect wholly owned subsidiary of Novartis, and (ii) the Separation and Distribution Agreement, dated as of October 25, 2025 (the “Separation Agreement”), among the Company, Bryce Therapeutics, Inc., a newly formed Delaware corporation and wholly owned subsidiary of the Company, and which on December 8, 2025, changed its name to Atrium Therapeutics, Inc. (“SpinCo”), and Novartis (with respect to certain sections therein), pursuant to which, on the terms and subject to the conditions set forth in the Separation Agreement, prior to the effective time of the Merger (the “Effective Time”), the Company will effect a pre-closing reorganization (the “Separation”), which (assuming no assets of the Company subject to the ROFN are sold to the ROFN Holder (as defined below)) will result in SpinCo owning, assuming or retaining all assets and liabilities of the Company and its subsidiaries exclusively related to their early stage precision cardiology programs, including AOC 1086 and AOC 1072, which target rare genetic cardiomyopathies, including phospholamban and Protein Kinase AMP-activated non-catalytic subunit Gamma 2 Syndrome, respectively, and certain collaboration agreements, including those with Bristol-Myers Squibb Company and Eli Lilly and Company (the “SpinCo Business”), and the Company owning, assuming or retaining all other assets and liabilities. The transfer of assets to SpinCo includes certain Company assets that triggered a right of first negotiation (“ROFN”) with an existing collaboration partner of the Company (the “ROFN Holder”). The Company is permitted to negotiate the sale of assets of the Company subject to the ROFN with the ROFN Holder, and, if an agreement is reached, consummate the sale of all or a portion of such assets. If such a sale of assets of the Company subject to the ROFN is consummated, SpinCo may receive less than all of the SpinCo Business. Following the Separation, but prior to the Effective Time, the Company will effect (i) a pro rata distribution of all of the issued and outstanding shares of SpinCo common stock, par value $0.001 per share (the “SpinCo Common Stock” and such a distribution, the “Distribution”), at the time of the Distribution to the Company’s stockholders as of the record date of the Distribution (the “Distribution Record Date”) at a ratio of one share of SpinCo Common Stock for every ten shares of Company common stock, par value $0.0001 per share (the “Company Common Stock”), held as of the Distribution Record Date or (ii) a sale of all of SpinCo to a third party (including to the ROFN Holder) (a “Permitted Third Party Sale”), and thereafter distribute the cash proceeds received by the Company, any of its affiliates or SpinCo from such sale, net of expenses incurred in connection with or related to the authorization, preparation, negotiation, execution and performance of such transaction and any definitive agreements related thereto to the Company’s stockholders, holders of options to purchase shares of Company Common Stock (the “Company Stock Options”) and holders of restricted stock units denominated in shares of Company Common Stock (together with the Company Stock Options, the “Company Equity Awards”), as of the chosen record date for distributing such proceeds, on a pro rata basis and subject to applicable tax withholding. In the case of either the Distribution or a Permitted Third Party Sale, the Company may also sell assets of the Company subject to the ROFN to the ROFN Holder and thereafter distribute the cash proceeds received by the Company, any of its affiliates or SpinCo from such sale, net of expenses incurred in connection with or related to the authorization, preparation, negotiation, execution and performance of such transaction and any definitive agreements related thereto (any such proceeds and/or any such proceeds received in connection with a Permitted Third Party Sale, the “Permitted Sale Proceeds”) to the Company’s stockholders and holders of Company Equity Awards, as of the chosen record date for distributing such proceeds, on a pro rata basis and subject to applicable tax withholding. In connection with the Distribution, holders of Company Equity Awards (subject to certain exceptions) as of the Distribution Record Date who are current service providers to SpinCo and its affiliates (including the Company) are entitled to receive Make Whole Awards (as defined in the accompanying proxy statement) that will be settled in shares of SpinCo Common Stock at a ratio of one share of SpinCo Common Stock per ten shares of Company Common Stock underlying each such Company Equity Award. If the Distribution is completed, SpinCo will operate as a separate, independent, publicly held company. If you are a stockholder of the Company and the Merger is consummated, each of your shares of Company Common Stock will be converted at the effective time of the Merger into the right to receive $72.00 in cash, without interest and subject to any applicable withholding taxes.
2.To consider and vote on a proposal to adjourn the Special Meeting, if necessary, desirable or appropriate or to solicit additional proxies if, at the time of the Special Meeting, there are an insufficient number of votes in favor of approving the Transactions Proposal. This Proposal No. 2 is the “Adjournment Proposal.”
3.To consider and vote on a non-binding, advisory proposal to approve compensation that may be paid or become payable to our named executive officers in connection with the Transactions (as defined below). This Proposal No. 3 is the “Non-Binding Merger-Related Compensation Proposal.”
|
| 2026-01-21 |
详情>>
内部人交易：
McCarthy Teresa等共交易11笔
|
| 2025-11-10 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-3.38美元,归母净利润-4.48亿美元,同比去年增长-103.38%
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益-2.11美元,归母净利润-2.73亿美元,同比去年增长-95.55%
|
| 2025-08-06 |
复牌提示：
2025-08-06 11:15:02 停牌，复牌日期 2025-08-06 11:20:02
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-0.9美元,归母净利润-1.16亿美元,同比去年增长-68.14%
|
| 2025-04-29 |
股东大会：
将于2025-06-10召开股东大会
会议内容 ▼▲
- 1.To elect three directors to serve as Class II directors for a three-year term expiring at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission;
4.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting.
|
| 2025-02-27 |
详情>>
业绩披露：
2022年年报每股收益-3.34美元,归母净利润-1.74亿美元,同比去年增长-47.44%
|
| 2025-02-27 |
详情>>
业绩披露：
2024年年报每股收益-2.89美元,归母净利润-3.22亿美元,同比去年增长-51.87%
|
| 2024-11-07 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-2.11美元,归母净利润-1.52亿美元,同比去年增长-22.87%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.08美元,归母净利润-2.2亿美元,同比去年增长-44.98%
|
| 2024-08-09 |
详情>>
业绩披露：
2024年中报每股收益-1.44美元,归母净利润-1.4亿美元,同比去年增长-40.46%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-0.79美元,归母净利润-6885.5万美元,同比去年增长-31.42%
|
| 2024-04-26 |
股东大会：
将于2024-06-13召开股东大会
会议内容 ▼▲
- 1.To elect three directors to serve as Class I directors for a three-year term expiring at the 2027 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified;
2.To ratify the appointment of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission;
4.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting.
|
| 2024-02-28 |
详情>>
业绩披露：
2023年年报每股收益-2.91美元,归母净利润-2.12亿美元,同比去年增长-21.97%
|
| 2023-04-28 |
股东大会：
将于2023-06-15召开股东大会
会议内容 ▼▲
- 1.To elect three directors to serve as Class III directors for a three-year term expiring at the 2026 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified;
2.To ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission;
4.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting.
|
| 2022-04-29 |
股东大会：
将于2022-06-15召开股东大会
会议内容 ▼▲
- 1.To elect Ms. Tamar Thompson and Mr. Eric Mosbrooker as Class II directors for a three-year term that expires at the 2025 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified;
2.To ratify the appointment of BDO USA, LLP as our independent public accounting firm for the fiscal year ending December 31, 2022;
3.To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission;
4.To consider and vote upon, on an advisory basis, whether the stockholder vote to approve the compensation of the named executive officers as required by Section 14A(a)(2) of the Securities Exchange Act of 1934, as amended, should occur every one, two or three years;
5.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-29 |
股东大会：
将于2021-06-16召开股东大会
会议内容 ▼▲
- 1.To elect three directors to serve as Class I directors for a three-year term expiring at the 2024 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified;
2.To ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting.
|